Now Available for Public Comment: Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials
1 study found for:    24100924 [PUBMED-IDS]
Show Display Options
Rank Status Study
1 Completed
Has Results
Docetaxel, Cisplatin, Pegfilgrastim, and Erlotinib Hydrochloride in Treating Patients With Stage IIIB or Stage IV Non-Small Cell Lung Cancer
Conditions: Adenocarcinoma of the Lung;   Adenosquamous Cell Lung Cancer;   Bronchoalveolar Cell Lung Cancer;   Large Cell Lung Cancer;   Non-small Cell Lung Cancer;   Recurrent Non-small Cell Lung Cancer;   Squamous Cell Lung Cancer;   Stage IIIB Non-small Cell Lung Cancer;   Stage IV Non-small Cell Lung Cancer
Interventions: Drug: cisplatin;   Biological: pegfilgrastim;   Drug: erlotinib hydrochloride;   Other: laboratory biomarker analysis;   Genetic: polymorphism analysis;   Other: pharmacogenomic studies;   Genetic: genetic linkage analysis;   Drug: docetaxel

Indicates status has not been verified in more than two years